Repurposing of already approved PARP-1 inhibitors for pathological conditions characterized by PARP-1 hyperactivity could be an attractive strategy, since it may offer accelerated and cost-effective therapeutic opportunities for different neurodegenerative diseases, including AD. The gene discussed is PARP1; the disease is Alzheimer disease.